Akceso is 10!

It was 10 years ago that Akceso Advisors AG was founded by our CEO Andras Incze.

He had the vision to build an expert team of independent advisors, serving as catalyst in pharmaceutical pricing and patient access.

A lot of great things have happened during the last decade, join us to celebrate the first 10 years of Akceso!

Watch

our celebration video playlist 

See

10 Years in 10+1 Numbers

Read

the special edition opinion piece in PRiMA Headlines June 2021 from Chris Shilling

Celebrate with us, watch our short videos!

Happy Birthday Akceso!

Happy Anniversary Akceso Advisors!

Unity in diversity has been a core part of our DNA since we started 10 years ago. It’s a crucial element of our success in engaging a diverse clientele, served by our diverse team, sharing two common characteristics: professionalism and aligned commitment towards patient access and our clients’ pricing success, for better public health worldwide.
To the next many years, with the exceptional Akceso team, with synergy in diversity!

Meet in the video with

András Incze – CEO and Founder (Switzerland)
Mária Tóth-Bagi – Strategy Advisor (Hungary)
Leo Smeets – Service Manager (The Netherlands)
Renáta Vincze – Pharmaceuticals Information Specialist (Romania)
Sophia Kessabi – Advisor (France)

See how Akceso became a global partner for pharma experts

We at Akceso Advisors can advise you on more than just the big markets. Our payer network and expertise in achieving access in smaller countries is equally precious to many of our clients, as shown by the large number of countries for which we delivered projects over the past 10 years.

0 +

clients served

4000

news articles in our monthly PRiMA Newsletter

80 +

completed projects

Akceso Verity Suite supports high-quality decision-making, enabling our clients to focus on the essential elements of their work. We are proud to provide modular, interconnected, state-of-the-art SaaS cloud solutions with outstanding user support from Akceso’s content experts. 

SMEs and Big pharma firms have obtained material benefits using our Verity Toolset. Contact us to explore together how you could.

+ 40% of patients having access to an emergency treatment for a life threatening condition

Akceso Advisors, an independent firm, developed an approach to achieve reimbursement approval for patients needing a life-saving Hereditary Angioedema drug in an EU country. A win-win for patients, the payer and the pharma manufacturer.

0 +

successfully launched products

150 M

price data points and counting in our ‘Verity Prices & Reimbursements’ database

0 +

therapy areas covered

In the past 10 years, our deep experience in launch sequence optimization has enabled clients to achieve a sales increase of up 12% from our advisory services.

An expert team of independent advisors, serving as catalyst in pharmaceutical pricing and patient access.

Contact us for a helping hand and explore how we can answer your patient access, pricing or policy challenge.

“10 YEARS AFTER – A PRICING & AKCESO RETROSPECTIVE” is the title of our special edition opinion piece in PRiMA Headlines June 2021.
Written by our talented advisor, Chris Shilling, the article exquisitely sums up the experiences, challenges and accomplishments of the past year both on a company and on an industry level. 
Read the full opinion piece and subscribe to our PRiMA Headlines Newsletter. Read about monthly highlights of developments in pricing, reimbursement and market access across the globe within the pharmaceutical industry.

10 YEARS AFTER – A PRICING & AKCESO RETROSPECTIVE

Chris Shilling

Chris Shilling, 27-June-2021

Akceso Advisors AG is ten years old!

We’re taking a moment to celebrate this milestone for the company. We’ve had an amazing time – a lot of highs, and of course a few lows – but as we look back on 10 years of serving our clients there is a definite sense of achievement. From the moment that András, our inspiring and determined CEO, took the decision to start something new, we’ve been driven by the excitement of using our expertise and skills to help committed people deliver what we all want – accessible medicines that deliver real value for patients, healthcare systems and the industry.

Things have changed significantly

Over those 10 years, some things have changed significantly – the use of Risk Sharing & Managed Entry Agreements in more and more countries and therapeutic areas, the growing influence of cross-country collaborations such as BeNeLuxAI and the Valetta Agreement, and the increasing focus in the US on controlling pricing are three major changes that continue to keep us busy. We’ve seen a major increase in projects trying to solve the challenge of identifying the appropriate pricing for orphan drugs, and the unique aspects of pricing and access models for game-changing cures.

We are proud to have made a difference, and particularly that our clients have returned to us when they’ve needed our specific skills, often driving us to find innovative solutions to their challenges

International Reference Pricing, Value-Based Pricing and Parallel Trade presentations at ISPOR

We’ve also been privileged to move from the sidelines of the pricing debate as keen supporters in the search for better ways to realise the value of medicine, to being involved at the centre of driving new thinking, delivering several high-profile presentations and discussions at ISPOR in 2020 and 2021 with our leading academic and industry partners on the topics of International Reference Pricing, Value-Based Pricing and Parallel Trade. As we send out this newsletter, we’re awaiting the exciting news of the publication of a paper exploring some key themes from these presentations in more depth.

Professionalism and aligned commitment towards patient access and our clients’ pricing success, for better public health worldwide

Several members of the Akceso team have worked in Pharma long enough to know that paths continually cross and themes repeat and reinvent themselves. Just as our company has grown and changed, so our clients have morphed – companies we knew well 10 years ago no longer exist, and some just starting out have become key players in emerging fields.

Unity in diversity has been a core part of our DNA since we started 10 years ago. It’s a crucial element of our success in engaging a diverse clientele, served by our diverse team, sharing two common characteristics: professionalism and aligned commitment towards patient access and our clients’ pricing success, for better public health worldwide. To the next many years, with the exceptional Akceso team, with synergy in diversity!

PRiMA Headlines

This article was published in our monthly PRiMA Headlines newsletter witch provides a monthly view of developments in Pricing, Reimbursement and Market Access across the globe. Since its launch in June 2015 we have covered more than 5000 stories from over 100 countries. Subscribe and be the happy reader of our newsletter!

The best tools for your challenges.

Get in touch with us and schedule a demo.

[contact-form-7 404 "Not Found"]

Join our mailing list!

The PRiMA Headlines Newsletter provides a monthly overview of developments in Pricing, Reimbursement and Market Access developments across the globe. Since its launch in June 2015 we have covered more than 5,000 stories from over 100 countries.

Scroll to Top